Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15639780 | 0.79 | KDM4E (0.44) | KDM4ESMN1; SMN2HIF1AMAPTTSHR | |
| SCHEMBL26110316 | 0.79 | KDM4E (0.44) | KDM4ESMN1; SMN2HIF1AMAPTTSHR | |
| SCHEMBL29572822 | 0.79 | KDM4E (0.44) | KDM4ESMN1; SMN2HIF1AMAPTTSHR | |
| SCHEMBL27549526 | 0.79 | KDM4E (0.55) | KDM4ESMN1; SMN2HIF1AMAPTTSHR | |
| SCHEMBL29691146 | 0.79 | KDM4E (0.44) | KDM4EMAPTTSHRKMT2AKCNN4 | |
| SCHEMBL15768092 | 0.76 | KDM4E (0.48) | KDM4ESMN1; SMN2HIF1AMAPTTSHR | |
| SCHEMBL30332406 | 0.76 | KDM4E (0.44) | KDM4ESMN1; SMN2HIF1AMAPTTSHR | |
| SCHEMBL29473273 | 0.76 | NPC1 (0.42) | KDM4EMAPTNPSR1 | |
| SCHEMBL30332490 | 0.76 | KDM4E (0.41) | KDM4ESMN1; SMN2HIF1AMAPTTSHR | |
| SCHEMBL30333162 | 0.76 | KDM4E (0.44) | KDM4ESMN1; SMN2HIF1AMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240352016-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | TAIZHOU EOC PHARMA CO., LTD (CN) | 2024-10-24 | — | — | US | disclosed |
| EP-4380930-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023016477-A9 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2024-04-25 | — | — | WO | disclosed |
| CN-117916235-A | Cyclin dependent kinase inhibitors | 泰州亿腾景昂药业股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023186065-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023046128-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2023-03-30 | — | — | WO | disclosed |
| WO-2023016477-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023016477-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352016-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | CDK2, CCNK, CDK1 | KDM4E 901/4885SMN1; SMN2 2926/4885HIF1A 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.